Last updated: 11/07/2018 03:39:50

Clinical study in children, 6 months to 3 years of age, to assess two dose levels of an experimental flu vaccine, using a licensed influenza virus vaccine, Vaxigrip® as the control

GSK study ID
111635
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Clinical study in children, 6 months to 3 years of age, to assess the immunogenicity and safety of two dose levels of thimerosal-free Fluviral® vaccine, using a licensed influenza virus vaccine, Vaxigrip® as the control
Trial description: Children younger than 5 years of age are at high risk for severe influenza disease (flu) and hospitalization due to flu. Scientists are in the process of re-evaluating the dosing initially based on whole virus vaccines to improve their efficacy in infants. In this study, we will compare two different dose levels of GSK1557482A flu vaccine. Another already approved flu vaccine made by a different company will be used as a control.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:

Number of subjects with any and grade 3 solicited local symptoms after vaccination

Timeframe: During the 4-day follow-up period (Days 0-3) after any vaccination

Number of subjects with any, grade 3 and related solicited general symptoms after vaccination

Timeframe: During the 4-day follow-up period (Days 0-3) after any vaccination

Number of subjects with any, grade 3 and related unsolicited adverse events (AEs) after vaccination

Timeframe: During the 28-day follow-up period (Days 0-27) after vaccination

Number of subjects with any, grade 3 and related medically-attended adverse events (MAEs) after vaccination

Timeframe: During the 28-day post-vaccination period

Number of subjects with any, grade 3 and related medically-attended adverse events (MAEs) after vaccination

Timeframe: During the 6-month safety follow up after vaccination

Number of subjects with any and related serious adverse events (SAEs) after vaccination

Timeframe: During the 28-day post-vaccination period

Number of subjects with any and related serious adverse events (SAEs) after vaccination

Timeframe: During the 6-month safety follow up after vaccination

Secondary outcomes:

Titers for serum Hemagglutination Inhibition (HI) antibodies

Timeframe: At Day 0 [PRE] and at Day 28 (for primed subjects) and Day 56 (for unprimed subjects) [POST]

Number of subjects seroconverted to HI antibodies

Timeframe: At Day 28 (for primed subjects) and at Day 56 (for unprimed subjects) [POST]

Number of subjects seroprotected against HI antibodies

Timeframe: At Day 0 [PRE] and at Day 28 (for primed subjects) and at Day 56 (for unprimed subjects) [POST]

Seroconversion factor for HI antibodies

Timeframe: At Day 28 (for primed subjects) and at Day 56 (for unprimed subjects) [POST]

Number of subjects with any and grade 3 solicited local symptoms after vaccination

Timeframe: During the 4-day follow-up period (Days 0-3) after any vaccination

Number of subjects with any, grade 3 and related solicited general symptoms after vaccination

Timeframe: During the 4-day follow-up period (Days 0-3) after any vaccination

Number of subjects with any, grade 3 and related unsolicited adverse events (AEs) after vaccination

Timeframe: During the 28-day follow-up period (Days 0-27) after vaccination

Number of subjects with any, grade 3 and related medically-attended adverse events (MAEs) after vaccination

Timeframe: During the 28-day post-vaccination period after vaccination

Number of subjects with any, grade 3 and related medically-attended adverse events (MAEs) after vaccination

Timeframe: During the 6-month safety follow up after vaccination

Number of subjects with any and related serious adverse events (SAEs) after vaccination

Timeframe: During the 28-day post-vaccination period

Number of subjects with any and related serious adverse events (SAEs) after vaccination

Timeframe: During the 6-month safety follow up after vaccination

Interventions:
Biological/vaccine: GSK Biologicals’ influenza vaccine GSK1557482A
Biological/vaccine: Vaxigrip
Enrollment:
390
Observational study model:
Not applicable
Primary completion date:
2009-19-08
Time perspective:
Not applicable
Clinical publications:
Langley JM et al. (2012) Immunogenicity and safety of 2 dose levels of a thimerosal-free trivalent seasonal influenza vaccine in children aged 6-35 months: A randomized, controlled trial. J Pediatr Infect Dis Soc.1(1):55-63.
Medical condition
Influenza
Product
GSK1557482A
Collaborators
Not applicable
Study date(s)
November 2008 to August 2009
Type
Interventional
Phase
2

Participation criteria

Sex
Female & Male
Age
6 - 36 months
Accepts healthy volunteers
Yes
  • A male or female child 6 months to < 3 years of age at the time of the vaccination, regardless of previous administration of influenza vaccine in a previous season;
  • Subjects must be in good health established by medical history and physical examination before entering into the study;
  • Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the administration of the study vaccine or planned use during the study period. Routine, registered childhood vaccinations are not an exclusion criterion;
  • History of hypersensitivity to any vaccine;

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Halifax, Nova Scotia, Canada, B3K 6R8
Status
Study Complete
Location
GSK Investigational Site
Ste-Foy, Québec, Canada, G1X 3V7
Status
Study Complete
Location
GSK Investigational Site
Sarnia, Ontario, Canada, N7T 4X3
Status
Study Complete
Location
GSK Investigational Site
Winnipeg, Manitoba, Canada, R3E 3P4
Status
Study Complete
Location
GSK Investigational Site
London, Ontario, Canada, N6H 4P2
Status
Study Complete
Location
GSK Investigational Site
Mississauga, Ontario, Canada, L5A 3V4
Status
Study Complete
Location
GSK Investigational Site
Langley, British Columbia, Canada, V3A 4H9
Status
Study Complete
Location
GSK Investigational Site
Calgary, Alberta, Canada, T3B 6A8
Status
Study Complete
Location
GSK Investigational Site
Mount Pearl, Newfoundland and Labrador, Canada, A1N 5B6
Status
Study Complete
Location
GSK Investigational Site
Charlottetown, Prince Edward Island, Canada, C1A 5N4
Status
Study Complete
Location
GSK Investigational Site
Hamilton, Ontario, Canada, L8L 5G8
Status
Study Complete
Location
GSK Investigational Site
Quebec City, Québec, Canada, G1V 4M6
Status
Study Complete
Location
GSK Investigational Site
Toronto, Ontario, Canada, M5G 1N8
Status
Study Complete
Location
GSK Investigational Site
Montreal, Québec, Canada, H3T 1C5
Status
Study Complete
Location
GSK Investigational Site
Newmarket, Ontario, Canada, L3Y 5G8
Status
Study Complete
Location
GSK Investigational Site
Sudbury, Ontario, Canada, P3E 1H5
Status
Study Complete
Location
GSK Investigational Site
Trois Rivières, Québec, Canada, G8T 7A1
Status
Study Complete
Location
GSK Investigational Site
London, Ontario, Canada, N6A 5R9
Status
Terminated/Withdrawn

Study documents

Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English

If you wish to request for full study report, please contact - [email protected]

Results overview

Results posted on ClinicalTrials.gov

Recruitment status
Completed
Actual primary completion date
2009-19-08
Actual study completion date
2009-19-08

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click here
Access to clinical trial data by researchers
Visit website